A citation-based method for searching scientific literature


List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
50

Mutational landscape and clonal architecture in grade II and III gliomas.
Hiromichi Suzuki, Kosuke Aoki, Kenichi Chiba, Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Teppei Shimamura, Atsushi Niida, Kazuya Motomura, Fumiharu Ohka,[...]. Nat Genet 2015
454
33

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
33

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
Adriana Olar, Khalida M Wani, Kristin D Alfaro-Munoz, Lindsey E Heathcock, Hinke F van Thuijl, Mark R Gilbert, Terri S Armstrong, Erik P Sulman, Daniel P Cahill, Elizabeth Vera-Bolanos,[...]. Acta Neuropathol 2015
178
16

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann, Jochen Meyer, Jörg Balss, David Capper, Wolf Mueller, Arne Christians, Jörg Felsberg, Marietta Wolter, Christian Mawrin, Wolfgang Wick,[...]. Acta Neuropathol 2009
776
16

Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
Tingting Liu, Guang Cheng, Xiaowei Kang, Yibin Xi, Yuanqiang Zhu, Kai Wang, Chao Sun, Jing Ye, Ping Li, Hong Yin. Neuroradiology 2018
24
16

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Marc Sanson, Yannick Marie, Sophie Paris, Ahmed Idbaih, Julien Laffaire, François Ducray, Soufiane El Hallani, Blandine Boisselier, Karima Mokhtari, Khe Hoang-Xuan,[...]. J Clin Oncol 2009
696
16

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
David E Reuss, Yasin Mamatjan, Daniel Schrimpf, David Capper, Volker Hovestadt, Annekathrin Kratz, Felix Sahm, Christian Koelsche, Andrey Korshunov, Adriana Olar,[...]. Acta Neuropathol 2015
168
16

Comparison between ultra-high and conventional mono b-value DWI for preoperative glioma grading.
Yu-Chuan Hu, Lin-Feng Yan, Qian Sun, Zhi-Cheng Liu, Shu-Mei Wang, Yu Han, Qiang Tian, Ying-Zhi Sun, Dan-Dan Zheng, Wen Wang,[...]. Oncotarget 2017
20
16

Interlaboratory comparison of IDH mutation detection.
Martin J van den Bent, C Hartmann, Matthias Preusser, Thomas Ströbel, Hendrikus J Dubbink, Johan M Kros, Andreas von Deimling, Blandine Boisselier, Marc Sanson, Kevin C Halling,[...]. J Neurooncol 2013
52
16

The value of multi ultra high-b-value DWI in grading cerebral astrocytomas and its association with aquaporin-4.
Yan Tan, Hui Zhang, Xiao-Chun Wang, Jiang-Bo Qin, Le Wang. Br J Radiol 2018
6
16



Advanced imaging in adult diffusely infiltrating low-grade gliomas.
Nail Bulakbaşı, Yahya Paksoy. Insights Imaging 2019
6
16

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Jason Beiko, Dima Suki, Kenneth R Hess, Benjamin D Fox, Vincent Cheung, Matthew Cabral, Nicole Shonka, Mark R Gilbert, Raymond Sawaya, Sujit S Prabhu,[...]. Neuro Oncol 2014
252
16

Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms.
Songtao Qi, Lei Yu, Hezhen Li, Yanghui Ou, Xiaoyu Qiu, Yanqing Ding, Huixia Han, Xuelin Zhang. Oncol Lett 2014
98
16

Accuracy of ADC derived from DWI for differentiating high-grade from low-grade gliomas: Systematic review and meta-analysis.
Qiang-Ping Wang, De-Qiang Lei, Ye Yuan, Nan-Xiang Xiong. Medicine (Baltimore) 2020
7
16




Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.
Chong Hyun Suh, Ho Sung Kim, Seung Chai Jung, Choong Gon Choi, Sang Joon Kim. Eur Radiol 2019
40
16

Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?
Hideo Nakamura, Ryuji Murakami, Toshinori Hirai, Mika Kitajima, Yasuyuki Yamashita. Acta Radiol 2013
22
16

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Takuya Watanabe, Sumihito Nobusawa, Paul Kleihues, Hiroko Ohgaki. Am J Pathol 2009
668
16

Prediction of Molecular Mutations in Diffuse Low-Grade Gliomas using MR Imaging Features.
Zeina A Shboul, James Chen, Khan M Iftekharuddin. Sci Rep 2020
16
16

Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
Hao Wu, Haipeng Tong, Xuesong Du, Hong Guo, Qiang Ma, Yulong Zhang, Xiaoyue Zhou, Heng Liu, Sunan Wang, Jingqin Fang,[...]. Eur Radiol 2020
8
16

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Christian Hartmann, Bettina Hentschel, Wolfgang Wick, David Capper, Jörg Felsberg, Matthias Simon, Manfred Westphal, Gabriele Schackert, Richard Meyermann, Torsten Pietsch,[...]. Acta Neuropathol 2010
504
16


Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging.
Fumiyuki Yamasaki, Kazuhiko Sugiyama, Megu Ohtaki, Yukio Takeshima, Nobukazu Abe, Yuji Akiyama, Junko Takaba, Vishwa Jeet Amatya, Taiichi Saito, Yoshinori Kajiwara,[...]. Eur J Radiol 2010
37
16


Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Rachel L Delfanti, David E Piccioni, Jason Handwerker, Naeim Bahrami, AnithaPriya Krishnan, Roshan Karunamuni, Jona A Hattangadi-Gluth, Tyler M Seibert, Ashwin Srikant, Karra A Jones,[...]. J Neurooncol 2017
42
16

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
Philipp Kickingereder, Felix Sahm, Alexander Radbruch, Wolfgang Wick, Sabine Heiland, Andreas von Deimling, Martin Bendszus, Benedikt Wiestler. Sci Rep 2015
158
16

Characterization of brain tumors by MRS, DWI and Ki-67 labeling index.
J A Calvar, F J Meli, C Romero, M L Calcagno, P Yánez, A R Martinez, H Lambre, A L Taratuto, G Sevlever. J Neurooncol 2005
65
16

Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.
Llewellyn E Jalbert, Adam Elkhaled, Joanna J Phillips, Evan Neill, Aurelia Williams, Jason C Crane, Marram P Olson, Annette M Molinaro, Mitchel S Berger, John Kurhanewicz,[...]. Sci Rep 2017
45
16

The correlation between MR diffusion-weighted imaging and pathological grades on glioma.
S-D Chen, P-F Hou, L Lou, X Jin, T-H Wang, J-L Xu. Eur Rev Med Pharmacol Sci 2014
14
16

Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index.
Ren Yan, Pang Haopeng, Feng Xiaoyuan, Wu Jinsong, Zhang Jiawen, Yao Chengjun, Qiu Tianming, Xiong Ji, Sheng Mao, Ding Yueyue,[...]. Neuroradiology 2016
35
16

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
16

Non-Coding RNAs in Glioma.
Ryte Rynkeviciene, Julija Simiene, Egle Strainiene, Vaidotas Stankevicius, Jurgita Usinskiene, Edita Miseikyte Kaubriene, Ingrida Meskinyte, Jonas Cicenas, Kestutis Suziedelis. Cancers (Basel) 2018
62
16

Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors.
Deborah T Blumenthal, Michal Yalon, Gilad W Vainer, Alexander Lossos, Shlomit Yust, Lior Tzach, Emanuela Cagnano, Dror Limon, Felix Bokstein. J Neurooncol 2016
46
16

Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer.
Jie Sun, Zicheng Zhang, Siqi Bao, Congcong Yan, Ping Hou, Nan Wu, Jianzhong Su, Liangde Xu, Meng Zhou. J Immunother Cancer 2020
87
16


Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.
Samantha N Reiss, Prakirthi Yerram, Lisa Modelevsky, Christian Grommes. J Immunother Cancer 2017
26
16

Long noncoding RNA 00460 (LINC00460) promotes glioma progression by negatively regulating miR-320a.
Li Feng, Min Rao, Yinan Zhou, Yunxin Zhang, Yonggang Zhu. J Cell Biochem 2019
13
16

The Prognostic and Therapeutic Value of PD-L1 in Glioma.
Ruo Qiao Chen, Feng Liu, Xin Yao Qiu, Xiao Qian Chen. Front Pharmacol 2019
42
16

Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review.
Ron Batash, Noam Asna, Pamela Schaffer, Nicole Francis, Moshe Schaffer. Curr Med Chem 2017
145
16

Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers.
Yongsheng Li, Tiantongfei Jiang, Weiwei Zhou, Junyi Li, Xinhui Li, Qi Wang, Xiaoyan Jin, Jiaqi Yin, Liuxin Chen, Yunpeng Zhang,[...]. Nat Commun 2020
105
16

Overview on current treatment standards in high-grade gliomas.
Alessia Pellerino, Federica Franchino, Riccardo Soffietti, Roberta Rudà. Q J Nucl Med Mol Imaging 2018
8
16

Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion.
Alison Roos, Zonghui Ding, Joseph C Loftus, Nhan L Tran. Front Oncol 2017
62
16

Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma.
Junseong Park, Chang Gon Kim, Jin-Kyoung Shim, Jong Hoon Kim, Hoyoung Lee, Jae Eun Lee, Min Hwan Kim, Keeok Haam, Inkyung Jung, Su-Hyung Park,[...]. Oncoimmunology 2018
25
16


Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
O Hamid, C Robert, A Daud, F S Hodi, W J Hwu, R Kefford, J D Wolchok, P Hersey, R Joseph, J S Weber,[...]. Ann Oncol 2019
193
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.